TITLE

Fluorescence In Situ Hybridization to Visualize Genetic Abnormalities in Interphase Cells of Acinar Cell Carcinoma, Ductal Adenocarcinoma, and Islet Cell Carcinoma of the Pancreas

AUTHOR(S)
Dewald, Gordon W.; Smyrk, Thomas C.; Thorland, Erik C.; McWilliams, Robert R.; Van Dyke, Daniel L.; Keefe, Jeannette G.; Belongie, Kimberly J.; Smoley, Stephanie A.; Knutson, Darlene L.; Fink, Stephanie R.; Wiktor, Anne E.; Petersen, Gloria M.
PUB. DATE
September 2009
SOURCE
Mayo Clinic Proceedings;Sep2009, Vol. 84 Issue 9, p801
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in Interphase cell nuclei (Interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas. PATIENTS AND METHODS: Between April 4, 2007, and December 4, 2008, interphase FISH was used to study paraffin-embedded preparations of tissue obtained from 18 patients listed in the Mayo Clinic Biospecimen Resource for Pancreas Research with a confirmed diagnosis of aclnar cell carcinoma, ductal adenocarcinoma, Islet cell carcinoma, or pancreas without evidence of neoplasla. FISH probes were used for chromosome loci of APC (see glossary at end of article for expansion of all gene symbols), BRCA2, CTNNB1, EGFR, ERBB2, CDKN2A, TP53, TYMP, and TYMS. These FISH probes were used with control probes to distinguish among various kinds of chromosome abnormalities of number and structure. RESULTS: FISH abnormalities were observed In 12(80%) of 15 patients with pancreatic cancer: 5 of 5 patients with acinar cell carcinoma, 5 of 5 patients with ductal adenocarcinoma, and 2 (40%) of 5 patients with islet cell carcinoma. All 3 specimens of pancreatic tissue without neoplasla had normal FISH results. Gains of CTNNB1 due to trisomy 3 occurred in each tumor with acinar cell carcinoma but in none of the other tumors In this study. FISH abnormalities of all other cancer genes studied were observed In all forms of pancreatic tumors In this Investigation. CONCLUSION: FISH abnormalities of CTNNB1 due to trisomy 3 were observed only In acinar cell carcinoma. FISH abnormalities of genes Implicated in familial cancer, tumor progression, and the 5-fluorouracil pathway were common but were not associated with specific types of pancreatic cancer.
ACCESSION #
44137672

 

Related Articles

  • CYP1B1 Polymorphisms and K -ras Mutations in Patients with Pancreatic Ductal Adenocarcinoma. José Pumarega; Tomàs López; Eva Morales; Núria Malats; Juli Rifà // Digestive Diseases & Sciences;May2008, Vol. 53 Issue 5, p1417 

    Abstract  The frequency of CYP1B1 polymorphisms in pancreatic cancer has never been reported. There is also no evidence on the relationship between CYP1B1 variants and mutations in ras genes (K-, H- or N-ras) in any human neoplasm. We analyzed the following CYP1B1 polymorphisms...

  • Long-term survival after resection of pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis: case report. Masui, Toshihiko; Kubota, Toyonari; Aoki, Keiko; Nakanishi, Yasutaka; Miyamoto, Takumi; Nagata, Junko; Morino, Koshiro; Fukugaki, Atsushi; Takamura, Michio; Sugimoto, Shinichi; Onuma, Hideyuki; Tokuka, Atsuo // World Journal of Surgical Oncology;2013, Vol. 11 Issue 1, p1 

    Pancreatic cancer patients with para-aortic lymph node metastasis have a poor prognosis and patients living longer than 3 years are rare. We had a patient with pancreatic cancer who survived for more than 10 years after removal of the para-aortic lymph node metastasis. A 57-year-old woman was...

  • Pancreaticoduodenectomy for pancreatic cancer: The Verona experience. MALLEO, GIUSEPPE; MARCHEGIANI, GIOVANNI; SALVIA, ROBERTO; BUTTURINI, GIOVANNI; PEDERZOLI, PAOLO; BASSI, CLAUDIO // Surgery Today;Apr2011, Vol. 41 Issue 4, p463 

    Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related mortality in the Western world. The current treatment is multimodal, and in resectable patients radical surgery represents the key-step toward long-term survival. Pancreaticoduodenectomy (PD) is the most widely...

  • Stromal biology and therapy in pancreatic cancer: a changing paradigm. Neesse, Albrecht; Algül, Hana; Tuveson, David A.; Gress, Thomas M. // Gut;Sep2015, Vol. 64 Issue 9, p1476 

    Pancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid tumours and poses an unsolved problem in cancer medicine. Despite the recent success of two combination chemotherapies for palliative patients, the modest survival benefits are often traded against...

  • HPB Surgery: Mayo Clinic: Diabetes can be controlled in patients after pancreas removal.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article informs that pancreatic cancer patients can manage diabetes after the complete removal of pancreas.

  • Choosing my own path. Ledger, Kate // Self;Dec2007, Vol. 29 Issue 12, p113 

    A personal narrative is presented which relates the author's battle against pancreatic cancer and decision to be treated by an oncologist who is using an unconventional chemotherapy regimen.

  • HIF-1 is a critical target of pancreatic cancer. Hao, Jihui // OncoImmunology;Sep2015, Vol. 4 Issue 9, pN.PAG 

    Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal digestive tract malignancies. Hypoxia-inducible factor (HIF-1) is over-expressed in pancreatic cancer and associated with poor prognosis. During the past several years, we focused on identifying the function of HIF-1 and the...

  • Perioperative and Long-Term Outcome after Standard Pancreaticoduodenectomy, Additional Portal Vein and Multivisceral Resection for Pancreatic Head Cancer. Kulemann, Birte; Hoeppner, Jens; Wittel, Uwe; Glatz, Torben; Keck, Tobias; Wellner, Ulrich; Bronsert, Peter; Sick, Olivia; Hopt, Ulrich; Makowiec, Frank; Riediger, Hartwig // Journal of Gastrointestinal Surgery;Mar2015, Vol. 19 Issue 3, p438 

    Introduction: The value of extended resection (portal vein, multivisceral) in patients with pancreatic adenocarcinoma (PDAC) is not well defined. We analyzed the outcome after standard resection (standard pancreaticoduodenectomy (SPR)), additional portal vein (PV) and multivisceral (MV)...

  • Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer†. Wolpin, B. M.; O'Reilly, E. M.; Ko, Y. J.; Blaszkowsky, L. S.; Rarick, M.; Rocha-Lima, C. M.; Ritch, P.; Chan, E.; Spratlin, J.; Macarulla, T.; McWhirter, E.; Pezet, D.; Lichinitser, M.; Roman, L.; Hartford, A.; Morrison, K.; Jackson, L.; Vincent, M.; Reyno, L.; Hidalgo, M. // Annals of Oncology;Jul2013, Vol. 24 Issue 7, p1792 

    Background We evaluated AGS-1C4D4, a fully human monoclonal antibody to prostate stem cell antigen (PSCA), with gemcitabine in a randomized, phase II study of metastatic pancreatic cancer. Patients and methods Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0/1 and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics